Recurrent Astrocytoma, IDH-Mutant, Grade 3

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Recurrent Astrocytoma, IDH-Mutant, Grade 3 trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 1/2

NCT05765812

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma…

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…

United States116 participantsStarted 2023-05-15

Treatment: Debio 0123, Temozolomide

RecruitingPhase 1

NCT06815029

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress…

This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial…

United States27 participantsStarted 2025-06-17

Treatment: Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy

All recent trials (5 shown)

SuspendedPhase 1

NCT06860594

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr…

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or ast…

United States30 participantsStarted 2025-07-30

Treatment: Biospecimen Collection, Computed Tomography

Active — Not RecruitingPhase 1

NCT03749187

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV gli…

United States78 participantsStarted 2019-04-03

Treatment: PARP Inhibitor BGB-290, Temozolomide (TMZ)

Recurrent Astrocytoma, IDH-Mutant, Grade 3

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma…

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress…

All recent trials (5 shown)

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr…

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma…

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress…

All recent trials (5 shown)

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr…

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children…